BMO Capital analyst Jeffrey Silber lowered his price target on Stericycle to $63 after its Q2 results, saying that while EPS beat expectations, organic revenue trends worsened on continued RWCS headwinds and softer Communication and Related Services segment revenues from recall events. The analyst keeps his Market Perform rating and notes that while the management is making progress in its business turnaround efforts, including the company's diversification into other sectors reducing some of the health-care end market risk, it may take some time for organic revenue trends to improve.

Completed previously disclosed workforce reduction in the first quarter of 2024 and are on track to realize an estimated $40-$45 million of in-year cost savings.